The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).
 
Deborah Marie Stephens
Honoraria - Genentech
Consulting or Advisory Role - Adaptive Biotechnologies; BeiGene; Epizyme; Innate Pharma; Karyopharm Therapeutics; Pharmacyclics/Janssen; TG Therapeutics
Research Funding - Acerta Pharma; ArQule; Gilead Sciences; Juno Therapeutics; Karyopharm Therapeutics; MingSight; Verastem
 
Anna Moseley
No Relationships to Disclose
 
Brian T. Hill
Honoraria - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis; Novartis; Pfizer; Pharmacyclics
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Genentech (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
John M. Pagel
Consulting or Advisory Role - Actinium Pharmaceuticals; AstraZeneca; BeiGene; Epizyme; Gilead Sciences; Loxo; MEI Pharma; MorphoSys; TG Therapeutics
 
Mazyar Shadman
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; Epizyme; Genentech; Innate Pharma; Kite, a Gilead company; MorphoSys; Pharmacyclics; Sound Biologics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene; Celgene (Inst); Genentech (Inst); Merck (Inst); MustangBio (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Michael Jordan Fisch
Employment - AIM Specialty Health
Stock and Other Ownership Interests - Anthem
Patents, Royalties, Other Intellectual Property - Healthcore, Inc. A subsidiary of Anthem, Inc.
 
Alexey Valeryevich Danilov
Stock and Other Ownership Interests - Abbvie
Honoraria - Dava Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Curis; Genentech/Roche; Gilead Sciences; Juno Therapeutics; Karyopharm Therapeutics; Seagen; Teva; TG Therapeutics; Verastem
Research Funding - Aptose Biosciences; AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech/Roche; Gilead Sciences; Takeda; Verastem
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche
 
David Ng
No Relationships to Disclose
 
Anthony R. Mato
Consulting or Advisory Role - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; Bristol-Myers Squibb/Pfizer; Celgene; Curio/Vaniam Group; DTRM; Johnson & Johnson; Loxo/Lilly; Merck; Pharmacyclics; TG Therapeutics; Verastem
Research Funding - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; DTRM; Genmab; Johnson & Johnson; LOXO; Nurix; Pharmacyclics; Regeneron; Sunesis Pharmaceuticals; TG Therapeutics
 
Danielle M. Brander
Honoraria - Genentech; TG Therapeutics; Verastem
Consulting or Advisory Role - Abbvie; Genentech/Abbvie; Novartis; Pfizer; Pharmacyclics; TG Therapeutics
Research Funding - Abbvie (Inst); ArQule (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); DTRM (Inst); Genentech (Inst); LOXO (Inst); MEI Pharma (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Teva; TG Therapeutics
Other Relationship - Novartis
 
Megan Othus
Consulting or Advisory Role - Cascadia Labs; Celgene; Daiichi Sankyo; Glycomimetics; Merck
Other Relationship - Celgene; Glycomimetics
 
Steve E. Coutre
Stock and Other Ownership Interests - Abbvie/Pharmacyclics (I)
Honoraria - Abbvie; Janssen Oncology; Pharmacyclics
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Genentech/Roche; Janssen Oncology; Pharmacyclics
Research Funding - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); Janssen Oncology (Inst); Kite/Gilead; Pharmacyclics (Inst)
Expert Testimony - Genentech; Pharmacyclics
Travel, Accommodations, Expenses - abbvie; BeiGene; Celgene; Genentech; Janssen Oncology; Pharmacyclics
 
Susan Mary O'Brien
Employment - University of California, Irvine
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Eisai; Gilead Sciences; GlaxoSmithKline; Janssen; Nova Research Company; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group
Research Funding - Acerta Pharma (Inst); Gilead Sciences (Inst); Kite, a Gilead company (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Harry Paul Erba
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Celgene; Daiichi Sankyo; Glycomimetics; Immunogen; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Kura Oncology; Macrogenics; Novartis; Pfizer; Takeda; Trillium Therapeutics
Speakers' Bureau - Abbvie/Genentech; Agios; Celgene; Incyte; Jazz Pharmaceuticals; Novartis
Research Funding - Abbvie; Abbvie (Inst); Agios (Inst); ALX Oncology (Inst); Amgen (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); Glycomimetics (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Macrogenics (Inst); Novartis (Inst); PTC Therapeutics (Inst)
Other Relationship - Celgene; Glycomimetics
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo